Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors

Drug Discovery Today

Volumn 5, Issue 8, 2000, Pages 344-353

  Sun, Li ^a   McMahon, Gerald ^a  

^a SUGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; IMATINIB; INDOLE DERIVATIVE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PD 166285; PD 173074; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; STAUROSPORINE DERIVATIVE; STI 412; SU 9902; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; CANCER INHIBITION; DRUG DEVELOPMENT; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034256094     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01534-8     Document Type: Review

References (64)

1. Folkman J. Tumor angiogenesis. therapeutic implication New Engl. J. Med. 285:1971;1182-1186.
2. Shawver L.K.et al. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today. 2:1997;50-63.
3. Gimbrone M.et al. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136:1972;261-276.
4. Scott P.A.E., Harris A.L. Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat. Rev. 20:1994;393-412.
5. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
6. Hayes A.J.et al. Antivascular therapy. a new approach to cancer treatment Br. Med. J. 318:1999;853-856.
7. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 58:1999;17-38.
8. Jekunen A.P., Kairemo K.J.A. Inhibition of malignant angiogenesis. Cancer Treat. Rev. 23:1997;263-286.
9. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;10705-10709.
10. Kendall R.L.et al. Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochem. Biophys. Res. Commun. 201:1994;326-330.
11. Millauer B.et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620.
12. Shalaby F.et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
13. Kim K.J.et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppressed tumour growth in vivo. Nature. 362:1993;841-844.
14. Vlodavsky I., Christofori G. Fibroblast growth factors in tumor progression and angiogenesis. Antiangiogenic Agents Cancer Ther. 1999;93-118.
15. D'Amore P.A.et al. Angiogenesis. Sci. Med. 6:1999;44-53.
16. Sundberg C.et al. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol. 143:1993;1377-1388.
17. Sato N.et al. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am. J. Pathol. 142:1993;1119-1130.
18. Brogi E.et al. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 90:1994;649-652.
19. Traxler P., Furet P. Strategies toward the design of the novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 82:1999;195-206.
20. Hamby J.M., Showalter H.D.H. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol. Ther. 82:1999;168-193.
21. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82:1999;231-239.
22. Fry W.D. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy. progression from reversible to irreversible inhibitors Pharmacol. Ther. 82:1999;207-218.
23. Trinks U.et al. Dianilinophthalimides. potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase J. Med. Chem. 37:1994;1015-1027.
24. Bridges A.J.et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 39:1996;267-276.
25. Gibson K.H.et al. Epidermal growth factor receptor tyrosine kinase. structure-activity relationships and antitumor activity of novel quinazolines Bioorg. Med. Chem. Lett. 7:1997;2723-2728.
26. Thompson A.M.et al. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 40:1997;3915-3925.
27. Rewcastle G.W.et al. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 41:1998;742-751.
28. Smaill J.B.et al. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J. Med. Chem. 42:1999;1803-1815.
29. Connolly C.J.C.et al. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 7:1997;2415-2420.
30. Traxler P.et al. 4-(Phenylamino)pyrrolopyrimidines. potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase J. Med. Chem. 39:1996;2285-2292.
31. Traxler P.et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors. 4-(phenylamino)pyrazolo[3,4-d]pyrimidines J. Med. Chem. 40:1997;3601-3616.
32. Zimmermann J.et al. Potent and selective inhibitors of the abl-kinase. phenylaminopyrimidine (PAP) derivatives Bioorg. Med. Chem. Lett. 7:1997;187-192.
33. Lavelle F. American association for cancer research 1997. progress and new hope in the fight against cancer Expert Opin. Invest. Drugs. 6:1997;771-775.
34. McMahon G.et al. Protein kinase inhibitors. structure determinants for target specificity Curr. Opin. Drug Discov. Develop. 1:1998;131-146.
35. Mohammadi M.et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 267:1997;955-960.
36. Schulze-Gahmen U.et al. Multiple modes of ligand recognition. crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentyladenine Proteins Struct. Funct. Genet. 22:1995;378-391.
37. Tong L.et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 4:1997;311-316.
38. Knighton D.R.et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;407-414.
39. Hubbard S.R.et al. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:1997;5572-5581.
40. Xu W.et al. Three-dimensional structure of the tyrosine kinase c-src. Nature. 385:1997;595-602.
41. Sicheri F.et al. Crystal structure of the src family tyrosine kinase Hck. Nature. 385:1997;602-609.
42. Sun, L. et al. Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydro-indol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ tyrosine kinases. J. Med. Chem. (in press).
43. Laird, A.D. et al. SU6668 is a potent anti-angiogenic and anti-tumor agent which induces regression of established tumors. Cancer Res. (in press).
44. Henke J.H.et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271:1996;695-701.
45. Sun L.et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones. a novel class of tyrosine kinase inhibitors that exhibit selectivity towards particular receptor tyrosine kinases J. Med. Chem. 41:1998;2588-2603.
46. Sun L.et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem. 42:1999;5120-5130.
47. Traxler P.et al. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J. Med. Chem. 42:1999;1018-1026.
48. Fry D.W.et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
49. Hennequin L.F.et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 42:1999;5369-5389.
50. Wedge S.R.et al. ZD4190. an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy Cancer Res. 60:2000;970-975.
51. Ward W.H.J.et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48:1994;659-666.
52. Fong T.A.T.et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106.
53. Angelov L.et al. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 59:1999;5536-5541.
54. Shaheen R.M.et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59:1999;5412-5416.
55. Dimitroff C.J.et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074. implications for combination treatment with photodynamic therapy Invest. New Drugs. 17:1999;121-135.
56. Mohammadi M.et al. Crystal structure of an angiogenesis inhibitor bond to the FGF receptor tyrosine kinase domain. EMBO J. 17:1998;5896-5904.
57. Druker B.J., Lydon N.B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105:2000;3-7.
58. Druker B.J.et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
59. Carroll M.et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 90:1997;4947-4952.
60. Fabbro D.et al. Inhibitors of protein kinases. CGP 41251, a protein kinase inhibitor with potential as an anticancer agent Pharmacol. Ther. 82:1999;293-301.
61. Menta E., Palumbo M. Antineoplastic agents 1998 - quinazoline derivatives. Curr. Opin. Ther. Patents. 8:1998;1627-1672.
62. Bold, G. et al. (Novartis) Phthalazines with angiogenesis inhibiting activity. WO9835958.
63. Traxler P. Tyrosine kinase inhibitors in cancer treatment (part II). Curr. Opin. Ther. Patents. 8:1998;1599-1625.
64. Wood J.et al. Pharmacological profile of a potent and orally active inhibitor of VEGF receptor tyrosine kinases. Proc. Am. Assoc. Cancer Res. 39:1998;655.